| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ARCH Venture Fund IX, L.P. | 13% | $16,102,995 | 36,597,716 | Robert Nelsen | 31 Dec 2024 | |||
| Foresite Capital Fund IV, L.P. | 9.2% | +36% | $11,951,232 | +$3,380,520 | 27,161,892 | +39% | James B. Tananbaum | 31 Mar 2025 |
| BlackRock, Inc. | 4.5% | $5,836,982 | 13,265,869 | BlackRock, Inc. | 31 Dec 2024 | |||
| Explore Investments LLC/DE | 5.4% | $9,202,330 | 1,040,964 | Explore Investments LLC | 25 Jul 2025 |
As of 30 Sep 2025, 2 institutional investors reported holding 650,353 shares of Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 per share (LYEL). This represents 3.4% of the company’s total 19,277,111 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 650,353 | $10,561,733 | -$15,728,473 | $16.24 | 2 |
| 2025 Q2 | 2,440,673 | $21,579,143 | -$465,374,552 | $8.84 | 6 |
| 2025 Q1 | 152,354,676 | $81,759,018 | +$815,948 | $0.54 | 111 |
| 2024 Q4 | 150,286,895 | $95,884,564 | +$14,590,227 | $0.64 | 101 |
| 2024 Q3 | 128,413,620 | $176,562,816 | -$7,308,646 | $1.38 | 115 |
| 2024 Q2 | 133,377,133 | $193,968,531 | -$1,417,363 | $1.45 | 114 |
| 2024 Q1 | 132,843,101 | $296,875,323 | +$4,211,832 | $2.23 | 124 |
| 2023 Q4 | 127,208 | $255,964 | $2.02 | 2 | |
| 2023 Q3 | 122,436,727 | $179,982,746 | +$185,145 | $1.47 | 100 |
| 2023 Q2 | 122,179,983 | $388,530,224 | +$15,242,932 | $3.18 | 97 |
| 2023 Q1 | 117,471,505 | $277,203,801 | +$818,441 | $2.36 | 95 |
| 2022 Q4 | 116,611,487 | $404,587,610 | +$13,810,470 | $3.47 | 92 |
| 2022 Q3 | 112,285,393 | $823,071,578 | +$50,660,796 | $7.33 | 86 |
| 2022 Q2 | 105,556,240 | $688,252,221 | +$42,217,102 | $6.52 | 71 |
| 2022 Q1 | 99,451,185 | $502,296,530 | +$55,150,752 | $5.05 | 75 |
| 2021 Q4 | 84,539,142 | $654,426,000 | -$25,699,393 | $7.74 | 74 |
| 2021 Q3 | 82,534,412 | $1,221,509,324 | +$57,610,023 | $14.80 | 61 |
| 2021 Q2 | 78,055,048 | $1,267,456,800 | +$1,267,456,786 | $16.24 | 51 |